Search Results

Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that patients now have exclusive access to VIVJOA® through AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies, subsidiaries of Walgreens Boots Alliance, Inc.

Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).

Mycovia Pharmaceuticals, Inc. today announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has published its phase 3 study evaluating the efficacy and safety of VIVJOA® (oteseconazole) capsules versus fluconazole in the treatment of severe vulvovaginal candidiasis (VVC) in Chinese women in the journal Antimicrobial Agents and Chemotherapy.

Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC).

Mycovia Pharmaceuticals, Inc. today announced the publication of its phase 3 ultraVIOLET study evaluating the efficacy and safety of VIVJOA™.

Mycovia Pharmaceuticals, Inc. has announced that it will present topline results from two studies evaluating VIVJOA™.

Mycovia Pharmaceuticals, Inc. today shared topline results from evaluating VIVJOA™ (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).

Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the publication of positive Phase 3 data evaluating VIVJOA™ (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) in the July edition of NEJM Evidence, available here.

Mycovia Pharmaceuticals, Inc. will sponsor a product theater showcase for its recently FDA-approved VIVJOA™ (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.